TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1390969

Group type: EXPERIMENTAL
Intervention: Both exercise and wax bath
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Wax bath only
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 3864167

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion therapy (100 micrograms/day, 3-hour intravenous infusion for three weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study: 31640191

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study: 30430724

Group type: COMPARATOR
Intervention: Single 2-g oral dose of TXA 2 h preoperatively followed by 1 g of oral TXA 3 h postoperatively (group B)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Single dose followed by 1 g of oral TXA 3 h and 7 h postoperatively (group C)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Single dose followed by 1 g of oral TXA 3 h, 7 h and 11 h postoperatively (group D)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Single dose followed by 1 g of oral TXA 3 h, 7 h, 11 h and 15 h postoperatively (group E)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 275
Study: 26937860

Group type: EXPERIMENTAL
Intervention: Proactive nurse participation in family conferences led by a physician
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with conferences led by a physician without a nurse
Number of subjects: 100
Study: 25527165

Group type: EXPERIMENTAL
Intervention: 75% pure glucose
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0.2% polidocanol diluted in 70% glucose
Number of subjects: 96
Study: 22833405

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived mononucleated cells (BM-MNC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no BM-MNC treatment)
Number of subjects: 60
Study: 20384942

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18541126

Group type: EXPERIMENTAL
Intervention: NSPN extract (360 mg Nigella sativa and 50 mg Phyllanthus niruri), administered 3 times daily for 7 days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: NSPN extract
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 15933495

Group type: EXPERIMENTAL
Intervention: Splinting
Number of subjects: 138

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: NCS parameters
Number of subjects: 138
Study: 12601404

Group type: EXPERIMENTAL
Intervention: Integrated chronic care management programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based care processes
Number of subjects: 0
Study: 10937982

Group type: EXPERIMENTAL
Intervention: Candoxatril 200 mg b.d. (n = 22)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Captopril 25-50 mg b.d. (n = 23)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 60
Study: 8656148

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Calcitriol (after transplantation)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Calcitriol (2 years post-transplant)
Number of subjects: 2
Study: 8433433

Group type: EXPERIMENTAL
Intervention: Completion angioscopy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Completion angiography
Number of subjects: 250
Study: 3315295

Group type: EXPERIMENTAL
Intervention: Transcutaneous cardiac pacing (PACE) in addition to standard advanced cardiac life support (ACLS) treatment
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard advanced cardiac life support (ACLS) care
Number of subjects: 202
Study: 31943768

Group type: COMPARATOR
Intervention: TNF‐α polymorphisms (rs1799964)
Number of subjects: 327

Group type: COMPARATOR
Intervention: TNF‐α polymorphisms (rs1800610)
Number of subjects: 327

Group type: COMPARATOR
Intervention: TGTA haplotype
Number of subjects: 327

Group type: COMPARATOR
Intervention: TGTG haplotype
Number of subjects: 327
Study: 29843254

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27294447

Group type: EXPERIMENTAL
Intervention: Centrally Assisted Collaborative Telecare (CACT)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 666
Study: 25270737

Group type: EXPERIMENTAL
Intervention: Multipronged intervention including educational brochure, personalized letter reminder, research assistant call, reminder letter, and automated phone call.
Number of subjects: 521

Group type: COMPARATOR
Intervention: Usual care with a form letter reminder and an automated reminder phone call.
Number of subjects: 521
Study: 23566563

Group type: EXPERIMENTAL
Intervention: Let's Talk! intervention (n = 34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 66
Study: 21760916

Group type: EXPERIMENTAL
Intervention: Peer counselling for exclusive breastfeeding (EBF)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Control (no peer counselling for EBF)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Length-for-age Z (LAZ) scores among children supplemented with Vitamin A
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Length-for-age Z (LAZ) scores among children not supplemented with Vitamin A
Number of subjects: 483
Study: 19322108

Group type: EXPERIMENTAL
Intervention: Pome fruit workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final data collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-pome fruit workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children of pome fruit workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children of non-pome fruit workers
Number of subjects: 0
Study: 16714186

Group type: EXPERIMENTAL
Intervention: Adjuvanted 30 microg formulation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted 7.5 microg, adjuvanted 15 microg, or non-adjuvanted 15 microg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 300

Group type: COMPARATOR
Intervention: Adjuvant
Number of subjects: 300
Study: 15274267

Group type: EXPERIMENTAL
Intervention: Percutaneous tenotomy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Open release
Number of subjects: 45
Study: 11343051

Group type: EXPERIMENTAL
Intervention: Vinblastine (6 mg/m², given intravenously every week)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Etoposide (150 mg/m²/d, given intravenously for 3 days every 3 weeks)
Number of subjects: 143
Study: 10342003

Group type: EXPERIMENTAL
Intervention: BIS monitoring with propofol anaesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BIS monitoring with sevoflurane anaesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (propofol without BIS monitoring)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (sevoflurane without BIS monitoring)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 80
Study: 7664216

Group type: COMPARATOR
Intervention: lisinopril (ACE inhibitor)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: losartan (Ang II receptor antagonist)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (thiazide diuretic)
Number of subjects: 135
Study: 2570004

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine three times daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine three times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1071694

Group type: EXPERIMENTAL
Intervention: Chlorothiazide (0.5 g twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metolazone (5 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chlorothiazide and Metolazone
Number of subjects: 20
Study: 30732456

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2539

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Complete revascularization after off-pump CABG
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization after off-pump CABG
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Complete revascularization after on-pump CABG
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization after on-pump CABG
Number of subjects: 2539

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization
Number of subjects: 2539
Study: 26974418

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine-bupivicaine mixture
Number of subjects: 120
Study: 23971894

Group type: EXPERIMENTAL
Intervention: Prescription opioid misuse
Number of subjects: 515
Study: 23465653

Group type: EXPERIMENTAL
Intervention: Metoprolol (5 mg IV over 5 min on commencement of bypass then 5 mg IV qid for 24h then 25-50 mg tds orally until discharge)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Combined metoprolol and amiodarone (300 mg over 1h starting shortly after the commencement of bypass, then 900 mg over 24h then 400 mg orally tds until discharge)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 215
Study: 19876659

Group type: EXPERIMENTAL
Intervention: Minimally invasive approach
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional open approach
Number of subjects: 59
Study: 18813410

Group type: EXPERIMENTAL
Intervention: Injection plus physiotherapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Brace plus physiotherapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Brace injection
Number of subjects: 92

Group type: COMPARATOR
Intervention: Bracing
Number of subjects: 92

Group type: COMPARATOR
Intervention: Injection alone
Number of subjects: 92
Study: 16368830

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine infusion (500 microg bolus before anesthesia induction, followed by 125 microg/h until end of surgery)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine infusion (500 microg bolus at end of surgery)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group received saline placebo during all three periods
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine infusion (500 microg bolus before anesthesia induction)
Number of subjects: 90
Study: 14561539

Group type: EXPERIMENTAL
Intervention: Implanon (etonogestrel 68 mg, single‐rod)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Norplant (levonorgestrel 36 mg, six capsules)
Number of subjects: 80
Study: 10773143

Group type: EXPERIMENTAL
Intervention: Omentoplasty (OP)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No Omentoplasty (NO)
Number of subjects: 167
Study: 2310661

Group type: EXPERIMENTAL
Intervention: Intravenous nisoldipine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous hydralazine
Number of subjects: 9
Study: 380737

Group type: EXPERIMENTAL
Intervention: Metronidazole (7-day course)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Povidone-iodine spray
Number of subjects: 0
Study: 31418516

Group type: EXPERIMENTAL
Intervention: Add-on insulin therapy
Number of subjects: 253
Study: 29078817

Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Atorvastatin (20 mg)
Number of subjects: 500
Study: 25377166

Group type: EXPERIMENTAL
Intervention: Nasal route (trainees)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral route (trainees)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nasal route (experts)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral route (experts)
Number of subjects: 100
Study: 24339307

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Levofloxacin 0.5%
Number of subjects: 50
Study: 22888611

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation
Number of subjects: 370

Group type: COMPARATOR
Intervention: Twice weekly iron supplementation
Number of subjects: 370
Study: 19325449

Group type: EXPERIMENTAL
Intervention: PHiD-CV
Number of subjects: 1650

Group type: COMPARATOR
Intervention: 7vCRM
Number of subjects: 1650
Study: 17257177

Group type: COMPARATOR
Intervention: Placebo (Group I, n = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg (Group II, n = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg and 20 mg/kg paracetamol (Group III, n = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gabapentin (Group II) and Gabapentin + Paracetamol (Group III)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg (Group II) and Gabapentin + Paracetamol (Group III)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (Group I)
Number of subjects: 75
Study: 15838188

Group type: EXPERIMENTAL
Intervention: Single-session intervention
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Six-session enhanced intervention
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1168
Study: 11961238

Group type: EXPERIMENTAL
Intervention: G-CSF (1 microg/kg IV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg IV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dexamethasone (1 mg/kg twice daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9719736

Group type: EXPERIMENTAL
Intervention: Reminder cards sent to defaulters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assistance of patients by lay health workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monetary incentives offered to patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased supervision of TB clinic staff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Directly-observed therapy (DOT)
Number of subjects: 0
Study: 9098476

Group type: EXPERIMENTAL
Intervention: 10 mg of cyproterone acetate and 20 mg of ethynyl‐estradiol in an inversal sequential scheme for six months
Number of subjects: 20
Study: 2478788

Group type: EXPERIMENTAL
Intervention: UD‐CG 115 BS 5 mg p.o.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: UD‐CG 115 BS 10 mg p.o.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Continuous treatment with 10 mg of UD‐CG 115 BS/day over 5 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dobutamine (optimal dose)
Number of subjects: 25
Study: 6993122

Group type: EXPERIMENTAL
Intervention: Early operation (n=28)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative treatment followed by delayed operation (n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (early operation and delayed operation)
Number of subjects: 60
Study: 31680331

Group type: EXPERIMENTAL
Intervention: 6 g fibrinogen concentrate
Number of subjects: 0
Study: 28228426

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) 2 capsules/d, 1.5 billion colony-forming units/capsule for 8 weeks
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 25755079

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (Zn group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 84
Study: 24628943

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 152

Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 22464209

Group type: EXPERIMENTAL
Intervention: Injection of embryo culture supernatant before embryo transfer
Number of subjects: 400
Study: 19924786

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No local therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Local treatment of both primary tumor and metastases
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Any local treatment of either primary tumor or metastases
Number of subjects: 120

Group type: COMPARATOR
Intervention: Absence of local treatment
Number of subjects: 120
Study: 18608312

Group type: EXPERIMENTAL
Intervention: 10-session protocol emphasizing values-based exposure and acceptance strategies
Number of subjects: 21

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 21
Study: 16043009

Group type: EXPERIMENTAL
Intervention: Home palliative care program
Number of subjects: 159

Group type: COMPARATOR
Intervention: No access to home palliative care program
Number of subjects: 159
Study: 12184365

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.q.) administration of AVA
Number of subjects: 0
Study: 10522995

Group type: EXPERIMENTAL
Intervention: MENT (7alpha‐methyl‐19‐nortestosterone)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MENT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wash-out phase
Number of subjects: 20
Study: 8534466

Group type: EXPERIMENTAL
Intervention: 70% N2O in 30% O2 administered by face mask for 120 seconds
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2.5 g of EMLA cream under an occlusive dressing for a minimum of 60 minutes
Number of subjects: 50
Study: 2178535

Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg orally, administered 1 hour before running
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo, administered after a low-fat breakfast before baseline pH recording
Number of subjects: 14
Study: 6121762

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol (various doses)
Number of subjects: 9
Study: 31109110

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (3-month one-on-one intervention)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard guidance (control group)
Number of subjects: 123
Study: 27839664

Group type: EXPERIMENTAL
Intervention: Therapeutic taping
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Placebo taping
Number of subjects: 26

Group type: COMPARATOR
Intervention: No taping
Number of subjects: 26
Study: 25967983

Group type: EXPERIMENTAL
Intervention: Web-based psychoeducational program (Diapason) for 3 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study: 23711165

Group type: EXPERIMENTAL
Intervention: Intervention group (more extensive advice and frequent follow-up)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (ordinary care)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study: 22068744

Group type: EXPERIMENTAL
Intervention: Cold water immersion (0-2°C) for 50 seconds
Number of subjects: 2

Group type: COMPARATOR
Intervention: Room temperature water immersion (22-24°C) for 50 seconds
Number of subjects: 2
Study: 19864219

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Air pollution (NO2 and PM10)
Number of subjects: 0
Study: 17533210

Group type: EXPERIMENTAL
Intervention: Personal model (age, sex, parental history of diabetes, body mass index)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Simple clinical model (including parental history of diabetes, obesity, hypertension, low HDL cholesterol, elevated triglycerides, impaired fasting glucose)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Complex clinical models (including 2-hour post-OGTT glucose, fasting insulin, C-reactive protein, Gutt insulin sensitivity index, homeostasis model insulin resistance)
Number of subjects: 160
Study: 15570070

Group type: EXPERIMENTAL
Intervention: Marimastat (10 mg bid)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Marimastat (10 mg bid) with plasma concentration ≥ 10 ng/mL
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Grade 2 or 3 MST
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Grade 0 or 1 MST
Number of subjects: 179
Study: 11222071

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced magnetic resonance angiography (Gd-MRA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 17
Study: 9458569

Group type: EXPERIMENTAL
Intervention: Video about infant immunization
Number of subjects: 227

Group type: COMPARATOR
Intervention: Oral presentation about infant immunization
Number of subjects: 227
Study: 8169430

Group type: EXPERIMENTAL
Intervention: 360 ELISA units (EU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 720 ELISA units (EU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1440 ELISA units (EU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All doses after two injections
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0-, 2-, and 4-month schedule
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0-, 1-, and 6-month schedule
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 12-month schedule
Number of subjects: 80
Study: 3280617

Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 29
Study: 30645153

Group type: EXPERIMENTAL
Intervention: 1 g IV acetaminophen
Number of subjects: 86

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 86